World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: IRCT
Last refreshed on: 22 February 2018
Main ID:  IRCT2015060122512N1
Date of registration: 2017-06-19
Prospective Registration: No
Primary sponsor: Mashhad University of Medical Sciences, Vice Chancellor for Research
Public title: The effect of Berberis Vulgaris extract, on Cutaneous Leishmaniasis
Scientific title: The Effect of Berberis Vulgaris hydro alcoholic extract, On Cutaneous Leishmaniasis patients in comparison with Glucantime and Placebo: A Clinical Trial
Date of first enrolment: 2015-02-18
Target sample size: 120
Recruitment status: Complete
URL:  http://en.irct.ir/trial/19404
Study type:  interventional
Study design:  Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.  
Phase:  3
Countries of recruitment
Iran (Islamic Republic of)
Contacts
Name: Dr Masoud Maleki   
Address:  Dermatology Departmen, Imam Reza hospital, Ebne Sina Street Mashhad Iran (Islamic Republic of)
Telephone: +98 51 3802 2510
Email: malekim@mums.ac.ir
Affiliation:  Dermatology Department & Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Scie
Name: Dr Masoud Maleki   
Address:  Dermatology Department, Imam Reza hospital, Ebne Sina Street Mashhad Iran (Islamic Republic of)
Telephone: +98 51 3802 2510
Email: malekim@mums.ac.ir
Affiliation:  Mashhad University of Medical Sciences
Key inclusion & exclusion criteria
Inclusion criteria: Inclusion criteria: Presence of cutaneous leishmaniasis with less than 6 months of clinical course; Not receive any treatment 3 months before; Age 8 years and above; Lesion diameter less than 3 cm; The number of lesion less than 5; The lesion on the limbs and trunk with the exception of joints’ surface.
Exclusion criteria: Pregnancy; Lactating; Receiving simultaneous treatment with other methods during treatment course; History of significance renal, Pulmonary and cardiovascular disease; Create a secondary infection of the wound; Deterioration of the condition of the patient during the study; Immune suppressor drugs consumption; Do not run commands therapy.

Exclusion criteria:

Age minimum: 12 years
Age maximum: no limit
Gender: Both
Health Condition(s) or Problem(s) studied
Cutaneous Leishmaniasis
Cutaneous Leishmaniasis.
Cutaneous Leishmaniasis
Intervention(s)
Intervention group: injection of intralesional Glucantime weekly for 8 weeks and topical use of Berberis Vulgaris extract three times daily for 8 weeks
Treatment - Drugs
Intervention 1: Intervention group: topical use of Berberis Vulgaris extract three times daily for 8 weeks. Intervention 2: Intervention group: injection of intralesional Glucantime weekly for 8 weeks and topical use of Berberis Vulgaris extract three times daily for 8 weeks. Intervention 3: Control group: injection of intralesional meglumine antimoniate (glucantime) weekly for 8 weeks and topical use of placebo three times daily for 8 weeks.
Intervention group: topical use of Berberis Vulgaris extract three times daily for 8 weeks
Control group: injection of intralesional meglumine antimoniate (glucantime) weekly for 8 weeks and topical use of placebo three times daily for 8 weeks
Primary Outcome(s)
Lesion size change. Timepoint: Weekly until 8 weeks. Method of measurement: Measuring the size of induration and ulcer by caliper.
Secondary Outcome(s)
Side effects: erythema, itching. Timepoint: Weekly. Method of measurement: Clinical evaluation.
Secondary ID(s)
Source(s) of Monetary Support
Mashhad University of Medical Sciences, Vice Chancellor for Research
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Ethics Committee of Mashhad University of Medical Sciences
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history